---
title: "Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297084117.md"
description: "Vancouver and Boston based Xenon Pharmaceuticals Inc. (Nasdaq: XENE) revealed their plans to present various data at the 16th European Epilepsy Congress (EEC) in Athens, Greece from September 5-9, 2026. The company, focused on neuroscience, aims to develop and market transformative medications for patients. This event will showcase crucial insights for the medical community and patients alike."
datetime: "2026-08-26T20:02:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297084117.md)
  - [en](https://longbridge.com/en/news/297084117.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297084117.md)
generator: "portal-rs"
---

# Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Vancouver and Boston based Xenon Pharmaceuticals Inc. (Nasdaq: XENE) revealed their plans to present various data at the 16th European Epilepsy Congress (EEC) in Athens, Greece from September 5-9, 2026. The company, focused on neuroscience, aims to develop and market transformative medications for patients. This event will showcase crucial insights for the medical community and patients alike.

### Related Stocks

- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)

## Related News & Research

- [Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78](https://longbridge.com/en/news/295283436.md)
- [Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds](https://longbridge.com/en/news/292462072.md)
- [Meiji Yasuda Asset Management Co Ltd. Makes New $5.41 Million Investment in United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/296770706.md)
- [SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race](https://longbridge.com/en/news/297220838.md)
- [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**